SCHEMBL19544607

SCHEMBL19544607

CCOC(=O)c1[nH]nc(-c2ccc(OC3CC4CC4C3)cc2)c1I

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 2/20 0.43
▸ AURKA O14965 1/20 0.43
▸ RIPK1 Q13546 1/20 0.43
▸ MAPT P10636 6/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ KDM4E B2RXH2 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ HPGDS O60760 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ HPGD P15428 2/20 0.36
▸ CDC25B P30305 2/20 0.36
▸ DUSP3 P51452 1/20 0.36
▸ TP53 P04637 1/20 0.35
▸ ALPL P05186 1/20 0.35
▸ TTK P33981 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19544883 0.91 MAPT (0.44) MAPK10AURKARIPK1MAPTALDH1A1
SCHEMBL19624848 0.89 MAPT (0.50) MAPK10AURKARIPK1MAPTALDH1A1
SCHEMBL19533582 0.85 HRH3 (0.35) MAPTALDH1A1KDM4EHRH3HSD17B10
SCHEMBL19544627 0.85 MAPK10 (0.44) MAPK10AURKARIPK1MAPTALDH1A1
SCHEMBL19624845 0.80 MAPT (0.54) MAPK10AURKARIPK1MAPTALDH1A1
SCHEMBL19544658 0.79 SCN9A (0.54) MAPK10AURKARIPK1MAPTALDH1A1
SCHEMBL25171648 0.78 DUSP3 (0.56) MAPK10AURKARIPK1MAPTALDH1A1
SCHEMBL19805499 0.78 KDM4E (0.49) MAPK10AURKARIPK1MAPTALDH1A1
SCHEMBL25060301 0.78 MAPT (0.44) MAPK10AURKARIPK1MAPTALDH1A1
SCHEMBL19533576 0.77 HRH3 (0.42) MAPTALDH1A1HRH3TTKMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3246317-B1 BTK INHIBITOR HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) 2023-02-22 — — EP disclosed
US-10662174-B2 BTK inhibitor HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2020-05-26 — — US disclosed
EP-3246317-A1 BTK INHIBITOR Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) 2017-11-22 — — EP disclosed
US-20170313683-A1 BTK INHIBITOR HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2017-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662174-B2 BTK inhibitor BTK, SYK, LYN MAPK10 383/4885AURKA 351/4885RIPK1 982/4885
US-20170313683-A1 BTK INHIBITOR BTK, SYK, LYN MAPK10 383/4885AURKA 351/4885RIPK1 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback